<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CLOFIBRATE</span><br/>(kloe-fy'brate)<br/><span class="topboxtradename">Atromid-S, </span><span class="topboxtradename">Claripex <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Novofibrate <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">cardiovascular drug</span>; <span class="classification">antilipemic</span>; <span class="classification">fibrate</span><br/><b>Prototype: </b>Fenofibrate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Structurally related to gemfibrozil. Reduces very low density lipoproteins (VLDL) to a greater extent than it reduces low
         density lipoproteins (LDL). Mechanism of action is unclear; it appears to inhibit cholesterol biosynthesis prior to transfer
         of triglycerides from liver to serum. Interferes with binding of free fatty acids to albumin and increases fecal excretion
         of neutral sterols. It affects the mobilization of cholesterol from tissue. Reduces platelet adhesiveness and increases release
         of ADH from posterior pituitary.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces very low density lipoproteins (VLDL) to a greater extent than it reduces low density lipoproteins (LDL).</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct for treatment of severe primary (type III) hyperlipidemia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Management of diabetes insipidus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Impaired renal or hepatic function, primary biliary cirrhosis; pregnancy (category C), lactation. Safe use in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of jaundice or hepatic disease; gallstones; peptic ulcer; hypothyroidism; cardiovascular disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hyperlipidemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g/d in 24 divided doses<br/><br/><span class="indicationtitle">Diabetes Insipidus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.52 g/d in 24 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>If gastric distress is a problem, administer drug with meals.</li>
<li>Preserve in closed, light-resistant containers at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> Increase or decrease in angina, CHF, arrhythmias. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, loose stools, diarrhea, flatulence, abdominal distress, gastritis, stomatitis, cholelithiasis. <span class="typehead">Hematologic:</span> Neutropenia, leukopenia, anemia, eosinophilia, <span class="speceff-life">agranulocytosis</span>, potentiation of anticoagulant effect. <span class="typehead">Metabolic:</span> Elevated AST and ALT. <span class="typehead">Musculoskeletal:</span> Flu-like symptoms. <span class="typehead">CNS:</span> Drowsiness, dizziness, headache. <span class="typehead"> Skin:</span>  Swelling and phlebitis at xanthoma sites, skin rash, allergy, urticaria, pruritus. <span class="typehead">Urogenital:</span> Renal insufficiency, impotence, decreased libido. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Clofibrate therapy may lead to increased <span class="alt">BSP</span> retention, <span class="alt">thymol</span> turbidity; increased <span class="alt">serum creatine phosphokinase (CPK);</span>
<span class="alt">proteinuria,</span> parodoxical increase in <span class="alt">LDL</span> or <span class="alt">cholesterol</span> levels (if there is a large decrease in VLDL level). Lower fasting <span class="alt">blood glucose</span> and <span class="alt">serum insulin</span> levels in patients with diabetes mellitus.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">oral anticoagulants</span> increase hypoprothrombinemia and increase risk of bleeding; <b>probenecid</b> increases effects of clofibrate; <span class="classification">sulfonylureas</span> increase hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 46 h. <span class="typehead">Distribution:</span> Distributed to extracellular space; crosses placenta; distribution into breast milk unknown.  <span class="typehead">Metabolism:</span>  Hydrolyzed in plasma to clofibric acid, which is further metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1235 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline and periodic lipid profile; periodic liver function tests, CBC, renal function tests, and determinations
            of plasma and urine steroid levels, serum electrolyte levels, and blood glucose.
         </li>
<li>Therapeutic response generally occurs during the first or second month of therapy. Rebound may occur in second or third month,
            followed by a further decrease, and may also occur with sudden withdrawal of drug.
         </li>
<li>Clofibrate therapy for increased serum cholesterol and triglycerides is generally withdrawn after 3 mo if the response is
            not adequate.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report flu-like symptoms (malaise, muscle soreness, aching, weakness) promptly to physician. Other reportable conditions include
            leukopenia, pulmonary edema, and renal insufficiency (see Appendix F) and gastric pain, nausea, and vomiting.
         </li>
<li>Women of childbearing years should be on birth control regimen. If pregnancy is desired, clofibrate therapy should be discontinued
            at least 2 mo before conception.
         </li>
<li>Do not self-dose with OTC drugs without the approval of physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>